Your session is about to expire
← Back to Search
Intravenous Lidocaine for Postoperative Pain
Study Summary
This trial will study the effects of lidocaine given during surgery on pain and opioid requirements afterwards, as well as the activity of immune cells.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What have been the previous investigations surrounding intravenous lidocaine (IVL) administration?
"Presently, a total of 118 studies are in progress related to intravenous lidocaine (IVL) with 31 trials being conducted at the Phase 3 level. While Calgary, Alberta is home to many clinical trials for IVL, there exists 1094 sites globally running these experiments."
Is the administration of lidocaine via intravenous infusion sanctioned by the FDA?
"The known safety of IVL led to it receiving a score of 3 on our scale; this Phase 4 trial has been approved for use."
How many participants have been selected for this research project?
"Affirmative. Clinicaltrials.gov reveals that the research, which was first advertised on April 29th 2019 and has been recently updated on October 1st 2021, is recruiting participants. The medical trial requires 60 individuals at a single site to complete it."
Are there any remaining slots in this experiment available to participants?
"This research study, originally posted on April 29th 2019, is currently seeking participants. Data hosted on clinicaltrials.gov corroborates this point and confirms that the trial was last updated October 1st 2021."
How is intravenous lidocaine (IVL) typically employed clinically?
"Cervical Syndrome is commonly managed with the use of Intravenous Lidocaine (IVL). In addition, this form of medication can be used for minor burn relief, post-transplant treatments and to improve bone density."
Share this study with friends
Copy Link
Messenger